{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:21:49Z","timestamp":1740122509874,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11239-021-02586-1","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T22:18:32Z","timestamp":1634422712000},"page":"607-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Direct oral anticoagulants for secondary stroke prevention in patients over 80\u00a0years of age: the role of geriatric functional status"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9494-160X","authenticated-orcid":false,"given":"Senta","family":"Frol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam Koro\u0161ec","family":"Hudnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana Podnar","family":"Sernec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi\u0161o","family":"\u0160abovi\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janja Pretnar","family":"Oblak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,16]]},"reference":[{"key":"2586_CR1","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jacc.2010.05.028","volume":"56","author":"R Marinigh","year":"2010","unstructured":"Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA (2010) Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol 56:827\u2013837","journal-title":"J Am Coll Cardiol"},{"key":"2586_CR2","doi-asserted-by":"publisher","first-page":"e005155","DOI":"10.1161\/JAHA.116.005155","volume":"6","author":"DA Lane","year":"2017","unstructured":"Lane DA, Skj\u00f8th F, Lip GY, Larsen TB, Kotecha D (2017) Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc 6:e005155","journal-title":"J Am Heart Assoc"},{"key":"2586_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","volume":"69","author":"Stroke Risk in Atrial Fibrillation Working Group","year":"2007","unstructured":"Stroke Risk in Atrial Fibrillation Working Group (2007) Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69:546\u2013554","journal-title":"Neurology"},{"key":"2586_CR4","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1161\/STROKEAHA.108.526988","volume":"40","author":"C Walraven","year":"2009","unstructured":"Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FR et al (2009) Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 40:1410\u20131416","journal-title":"Stroke"},{"key":"2586_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"2586_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"2586_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"issue":"6","key":"2586_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/1747493017700663","volume":"12","author":"G Ntaios","year":"2017","unstructured":"Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P et al (2017) Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 12(6):589\u2013596","journal-title":"Int J Stroke"},{"issue":"6","key":"2586_CR9","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1161\/STROKEAHA.118.023959","volume":"50","author":"NB Sur","year":"2019","unstructured":"Sur NB, Wang K, Di Tullio MR, Gutierrez CM, Dong C, Koch S et al (2019) Disparities and temporal trends in the use of anticoagulation in patients with ischemic stroke and atrial fibrillation. Stroke 50(6):1452\u20131459","journal-title":"Stroke"},{"key":"2586_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejim.2020.05.001","volume":"79","author":"D Sagris","year":"2020","unstructured":"Sagris D, Leventis I, Georgiopoulos G, Korompoki E, Makaritsis K, Vemmos K et al (2020) Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. Eur J Intern Med 79:31\u201336","journal-title":"Eur J Intern Med"},{"key":"2586_CR11","doi-asserted-by":"publisher","first-page":"j510","DOI":"10.1136\/bmj.j510","volume":"356","author":"PB Nielsen","year":"2017","unstructured":"Nielsen PB, Skj\u00f8th F, S\u00f8gaard M, Kj\u00e6ldgaard JN, Lip GY, Larsen TB (2017) Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 356:j510","journal-title":"BMJ"},{"key":"2586_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/joim.12683","volume":"283","author":"L Staerk","year":"2018","unstructured":"Staerk L, Gerds TA, Lip GYH, Ozenne B, Bonde AN, Lamberts M et al (2018) Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med 283:45\u201355","journal-title":"J Intern Med"},{"key":"2586_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ahj.2017.08.018","volume":"198","author":"MV Huisman","year":"2018","unstructured":"Huisman MV, Rothman KJ, Paquette M et al (2018) Two-year follow up of patients treated with dabigatran for stroke prevention in atrial fibrillation: global registry on long-term antithrombotic treatment in patients with atrial fibrillation (GLORIA-AF) registry. Am Heart J 198:55\u201363","journal-title":"Am Heart J"},{"key":"2586_CR14","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","volume":"37","author":"JP Bassand","year":"2016","unstructured":"Bassand JP, Acetta G, Camm AJ et al (2016) Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 37:2882\u20132889","journal-title":"Eur Heart J"},{"key":"2586_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.archger.2018.12.013","volume":"81","author":"D Caldeira","year":"2019","unstructured":"Caldeira D, Nunes-Ferreira A, Rodrigues R, Vicente E, Pinto FJ, Ferreira JJ et al (2019) Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis. Arch Gerontol Geriatr 81:209\u2013214","journal-title":"Arch Gerontol Geriatr"},{"key":"2586_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","volume":"9","author":"HC Diener","year":"2012","unstructured":"Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, RE-LY study group et al (2012) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 9:1157\u20131163","journal-title":"Lancet Neurol"},{"key":"2586_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","volume":"11","author":"GJ Hankey","year":"2012","unstructured":"Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A et al (2012) Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11:315\u2013322","journal-title":"Lancet Neurol"},{"key":"2586_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","volume":"11","author":"JD Easton","year":"2012","unstructured":"Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L et al (2012) Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 11:503\u2013511","journal-title":"Lancet Neurol"},{"key":"2586_CR19","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","volume":"33","author":"L Friberg","year":"2012","unstructured":"Friberg L, Rosenqvist M, Lip GY (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J 33:1500\u20131510","journal-title":"Eur Heart J"},{"key":"2586_CR20","unstructured":"Bagar S, Sluga D\u010c, Hladnik M, Jandl M, Majcan Kopilovi\u0107 I, Kravanja M et al. (2018) Zdravstveno stanje prebivalstva: umrljivost. In: Zdravstveni statisti\u010dni letopis Slovenije 2018. National institute of public health (NIJZ). https:\/\/www.nijz.si\/sites\/www.nijz.si\/files\/uploaded\/publikacije\/letopisi\/2018\/2.1_umrljivost_2018_5.pdf. Accessed 29 Dec 2020"},{"key":"2586_CR21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40261-020-00967-7","volume":"40","author":"S Frol","year":"2020","unstructured":"Frol S, Sernec LP, Hudnik LK, \u0160abovi\u010d M, Oblak JP (2020) Effectiveness and safety of direct oral anticoagulants in the secondary stroke prevention of elderly patients: Ljubljana registry of secondary stroke prevention. Clin Drug Investig 40:1053\u20131061","journal-title":"Clin Drug Investig"},{"key":"2586_CR22","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD et al (2014) Guidelines for the prevention of stroke in patients with stroke and transient ischaemic attack: a guideline for healthcare professionals from the American heart association\/American stroke association. Stroke 45:2160\u20132236","journal-title":"Stroke"},{"key":"2586_CR23","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhame P, Potpara T et al (2018) The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330\u20131393","journal-title":"Eur Heart J"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-021-02586-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T08:13:04Z","timestamp":1649405584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-021-02586-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,16]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2586"],"URL":"https:\/\/doi.org\/10.1007\/s11239-021-02586-1","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"type":"print","value":"0929-5305"},{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2021,10,16]]},"assertion":[{"value":"6 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In the past 2\u00a0years, JPO, MS and SF have received honoraria for oral presentations from Bayer, Boehringer Ingelheim and Pfizer. LSP and LHK have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Slovenian National Medical Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consents were provided by the patient or patient\u2019s relative.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}